CRT logo

Cross Timbers Royalty Trust

CRTNASDAQ
US Equity
$11.96▼ $0.35 (−2.92%)
🌅 Pre-market$11.96▲ 0.00%Regular close · extended-hours price shown
🔔
Track CRT
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 2.9%
7d▼ 1.7%
14d▼ 3.6%
30d▲ 12.9%
ytd▲ 50.5%
1y▲ 55.7%
🏦Market Cap
$430B
Large Cap
📈Revenue Growth (YoY)
+24.4%
Healthy
📊Gross Margin
53.1%
Healthy
💵FCF Margin
26.8%
Strong
⚖️P/S Ratio
2.2x
Cheap
Otter Score
84
Good

Trading Snapshot

Day Range
$11.89 – $12.14
52-Week Range
$189.81 – $402.68
Volume
$5.17B
Avg Volume
$5.24B
Shares Outstanding
35.99B
Next Earnings
Nov 3, 2026

Fundamentals Snapshot

Annual Revenue
$6M
Last Q Revenue
$1M
P/E Ratio
9.5
P/S Ratio
2.2x
EPS (TTM)
$30.06
Dividend Yield
1.79%
Dilution (1yr)
+0.0%

Why Investors Own CRT

  • ✓High-growth profile — revenue up +24.4% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 53% gross margin and 27% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

CRT logo

Cross Timbers Royalty Trust

CRT
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$6M▼ −11.8% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
95.3%▼ −4.7% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$4M▼ −20.1% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$0▲ +0.0% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
6.0M▲ +0.0% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$2M▲ +$764K YoY
StockOtter · stockotter.space

About Cross Timbers Royalty Trust

A company profile for Cross Timbers Royalty Trust isn’t available yet — check back soon.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Good
84/100

Analyst Price Target

ⓘ
Average Target
$15.16
▲ +26.8% Upside
High Target$16.51
Low Target$11.28
Based on 19 analysts

Latest News & Updates

Defense World·2d ago

Cross Timbers Royalty Trust (CRT) To Go Ex-Dividend on September 30th

Cross Timbers Royalty Trust (NYSE: CRT - Get Free Report) announced a monthly dividend on Friday, September 18th. Shareholders of record on Wednesday, September 30th will be paid a dividend of $0.0643 per share by the oi

PRNewsWire·12d ago

CROSS TIMBERS ROYALTY TRUST DECLARES SEPTEMBER CASH DISTRIBUTION

DALLAS, Sept. 18, 2026 /PRNewswire/ -- Argent Trust Company, as Trustee of the Cross Timbers Royalty Trust (the "Trust") (NYSE: CRT), today declared a cash distribution to the holders of its units of beneficial interest

GuruFocus·12d ago

Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as Perioperative Treatment for Adults With Resectable Muscle-Invasive Bladder Cancer (MIBC)

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the European Medicines Agency's Committee for Medicinal Products for Hu

GuruFocus·13d ago

Innate Pharma Reports First Half 2026 Business Update and Financial Results

Regulatory News:Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today reported its consolidated financial results for t

GuruFocus·16d ago

TAGRISSO® (osimertinib) demonstrated unprecedented eight-year landmark survival in early-stage EGFR-mutated lung cancer in ADAURA Phase III trial

Updated exploratory results from the ADAURA Phase III trial showed AstraZeneca's TAGRISSOÂ (osimertinib) demonstrated a sustained, clinically meaningful overal

PRNewsWire·Aug 21

CROSS TIMBERS ROYALTY TRUST DECLARES AUGUST CASH DISTRIBUTION

DALLAS, Aug. 21, 2026 /PRNewswire/ -- Argent Trust Company, as Trustee of the Cross Timbers Royalty Trust (the "Trust") (NYSE: CRT), today declared a cash distribution to the holders of its units of beneficial interest o